Open Angle Glaucoma Market Set for Strong Growth as Aging Population and Advanced Treatment Technologies Drive DemandOpen Angle Glaucoma Market Overview
The Open Angle Glaucoma Market is expanding as the prevalence of glaucoma increases worldwide and healthcare systems place greater emphasis on early diagnosis, intraocular pressure management, and preservation of vision. According to Maximize Market Research, the Global Open Angle Glaucoma Market was valued at USD 7.88 billion in 2023 and is expected to grow at a CAGR of 8% from 2024 to 2030, reaching approximately USD 13.51 billion by 2030.
Open-angle glaucoma is among the most prevalent forms of glaucoma and typically progresses gradually, often without noticeable symptoms during its early stages. The growing aging population is a major market driver because advanced age is strongly associated with increasing glaucoma risk. Rising prevalence of chronic conditions such as diabetes and hypertension is also contributing to demand for glaucoma screening, diagnosis, and treatment.
Growing awareness of eye health and the importance of routine examinations is supporting earlier diagnosis. Ophthalmologists increasingly rely on intraocular pressure measurement, optic-nerve assessment, visual-field testing, and advanced imaging technologies to identify disease progression. These developments are expanding demand for both diagnostic and therapeutic solutions.
Technological innovation is creating substantial opportunities across the market. Optical coherence tomography (OCT) enables detailed imaging of the retina and optic nerve, supporting earlier identification of structural changes. Meanwhile, minimally invasive glaucoma surgery (MIGS), laser procedures, and advanced drug-delivery systems are providing additional treatment options.
Sustained-release drug delivery is particularly promising because conventional eye drops require regular administration and may present adherence challenges. Long-acting implants and ocular delivery systems could reduce treatment frequency while maintaining more consistent therapeutic exposure. Continued pharmaceutical and medical-device research is therefore expected to create new opportunities for market participants.
* Download the Full Market Report: https://www.maximizemarketresearch.com/request-sample/189238/
U.S. Market Trends and Investment
North America accounted for a significant share of the global market in 2023, supported by established healthcare infrastructure, high glaucoma prevalence, patient awareness, advanced diagnostics, research activity, and favorable reimbursement conditions. The United States remains a major center for glaucoma innovation. In 2025, FDA records showed approvals of generic latanoprostene bunod and bimatoprost products for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, demonstrating continued expansion of treatment availability. Investment is also moving toward sustained-release and minimally invasive approaches. Glaukos reported more than $750 million invested in R&D since 2018 and a broad 2025 pipeline spanning sustained-release, micro-scale, and bio-activated glaucoma technologies. In February 2025, Perceive Pharma raised $15 million in Series A financing to advance its glaucoma neuroprotection program toward clinical readiness. These developments highlight growing U.S. investment in therapies that can improve disease control and reduce treatment burden.
Market Segmentation
The Open Angle Glaucoma Market is segmented by Type, Drug Class, Application, and End User.
By type, Open-Angle Glaucoma dominated the market in 2023, reflecting its status as the most common form of glaucoma and the large patient population requiring long-term disease management.
By drug class, Prostaglandins held the dominant position in 2023 because medicines such as latanoprost and bimatoprost effectively lower intraocular pressure by increasing aqueous-humor outflow. They are widely used as first-line treatment options because of their effectiveness and tolerability.
By application, Hospital Pharmacies dominated the market in 2023, supported by the role of hospitals and healthcare facilities in glaucoma diagnosis and treatment. By end user, Hospitals accounted for the highest market share in 2023, reflecting their access to specialized ophthalmologists, diagnostic equipment, surgical capabilities, and glaucoma medications.
Open Angle Glaucoma Market,Key Players
1.Allergan (now AbbVie) - United States
2.Pfizer Inc. - United States
3. Merck & Co., Inc. - United States
4.Johnson & Johnson - United States
5.Aerie Pharmaceuticals, Inc. - United States
6.Glaukos Corporation - United States
7.Reichert Technologies - United States
8.Diopsys, Inc. - United States
9.Quidel Corporation - United States
10. Ivantis, Inc. - United States
11. Sight Sciences, Inc. - United States
12. Novartis International AG – Switzerlan
13.Zeiss Group – Germany
14. Carl Zeiss Meditec AG – Germany
15.NICOX SA - France
16.Sensimed AG – Switzerland
17.Lumenis Ltd. – Israel
18. Santen Pharmaceutical Co., Ltd. – Japan
19.Otsuka Pharmaceutical Co., Ltd. - Japan
20. Senju Pharmaceutical Co., Ltd. – Japan
21.Nidek Co., Ltd. - Japan
22. Canon Medical Systems Corporation - Japan
* Download the Full Market Report: https://www.maximizemarketresearch.com/request-sample/189238/
Competitive Analysis
The MMR report identifies Allergan (now AbbVie), Pfizer Inc., Merck & Co., Inc., Johnson & Johnson, Aerie Pharmaceuticals, Inc., Glaukos Corporation, Reichert Technologies, Diopsys, Inc., Quidel Corporation, Ivantis, Inc., Sight Sciences, Inc., Novartis International AG, Zeiss Group, Carl Zeiss Meditec AG, NICOX SA, Sensimed AG, Lumenis Ltd., Santen Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Senju Pharmaceutical Co., Ltd., Nidek Co., Ltd., and Canon Medical Systems Corporation as key companies.
The supplied MMR report does not disclose individual market-share percentages for the five largest companies, so unsupported company-specific shares are not assigned.
Glaukos Corporation is advancing sustained-release and interventional glaucoma technologies. Its iDose platform is designed to continuously deliver therapy inside the eye, addressing treatment adherence challenges associated with topical medications. The company reported an extensive 2025 pipeline focused on open-angle glaucoma and ocular hypertension.
Santen Pharmaceutical Co., Ltd. has strengthened its position in glaucoma treatment through OMLONTI, an ophthalmic therapy approved by the FDA for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Johnson & Johnson continues to participate in ophthalmic innovation and was among the investors backing Perceive Pharma's 2025 Series A financing for glaucoma neuroprotection research.
Sight Sciences, Inc. is expanding interventional glaucoma treatment through technologies such as the OMNI Surgical System, which is designed to address resistance across the conventional aqueous-humor outflow pathway. Company materials in 2025 highlighted extensive clinical experience with the technology.
Aerie Pharmaceuticals, Inc. remains among the companies identified in the MMR competitive landscape, contributing to the broader pharmaceutical innovation ecosystem for glaucoma management.
Regional Analysis
North America held a significant share of the Open Angle Glaucoma Market in 2023, supported by advanced healthcare infrastructure, high disease awareness, sophisticated diagnostic technologies, and strong research and development activity. The United States is the primary regional growth engine because of its established ophthalmology ecosystem and high availability of advanced pharmaceutical and surgical treatments.
The U.S. market is also benefiting from increasing development of minimally invasive procedures and sustained-release therapies. Investment in glaucoma research is continuing through both commercial and nonprofit channels. In March 2025, the Glaucoma Research Foundation announced nine Shaffer Research Grants worth $55,000 each to support innovative glaucoma research.
Japan is another important market because of its aging population, advanced healthcare infrastructure, and established ophthalmic pharmaceutical industry. Santen, Otsuka, Senju, Nidek, and Canon Medical Systems are among the Japanese companies identified in the MMR competitive landscape.
China also represents a significant long-term opportunity as its aging population, healthcare expenditure, ophthalmic infrastructure, and awareness of eye diseases continue to develop.
Conclusion
The Global Open Angle Glaucoma Market is projected to grow from USD 7.88 billion in 2023 to USD 13.51 billion by 2030, representing an 8% CAGR during 2024–2030.
In our view, the strongest growth opportunity lies in long-acting drug delivery, minimally invasive glaucoma surgery, advanced diagnostics, and therapies designed to improve treatment adherence. The transition from frequent topical administration toward sustained-release and procedure-based treatment could significantly reshape the competitive landscape.
As the global aging population grows and glaucoma diagnosis improves, demand for solutions that preserve vision while reducing treatment burden will continue to increase. Companies capable of combining pharmaceutical innovation with advanced drug-delivery systems, digital monitoring, and minimally invasive technologies are likely to capture significant opportunities in the evolving glaucoma treatment market.
About Maximize Market Research
Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting firm known for delivering accurate, actionable, and data-driven insights. Our expertise spans diverse industries — including medical devices, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. We provide services such as market-validated forecasts, competitive intelligence, strategic consulting, and industry impact analysis, helping businesses navigate market complexities and achieve sustainable growth.
Contact Maximize Market Research
MAXIMIZE MARKET RESEARCH PVT. LTD.
2nd Floor, Naval IT Park Phase 3,
Pune-Bangalore Highway, Narhe,
Pune, Maharashtra 411041, India.
? +91 9607365656
? [email protected]
Comments